Valiant Tan, MD
Hematology-Oncology · Chesapeake, VANPI 1154326718
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.7%), other and speaking fees — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Novartis at 38.0% of the total. 2025 is the largest year on record at $1,315, 5.0 times the $265 reported in 2019.
Across 35 payments — averaging $88.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Rigel Pharmaceuticals, Inc.$186
- Stryker$155
- Array Biopharma Inc$150
- Stemline Therapeutics Inc.$126
- Novocure Inc.$126
- plus $1K from 15 others
What the payments were for
- Speaking & faculty fees$1505%
- Food & beverage$1,72856%
- Education$451%
- Other$1,18038%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 12 | $1,180 |
| Rigel Pharmaceuticals, Inc. | 2 | $186 |
| Stryker | 1 | $155 |
| Array Biopharma Inc | 1 | $150 |
| Stemline Therapeutics Inc. | 1 | $126 |
| Novocure Inc. | 1 | $126 |
| Incyte Corporation | 1 | $125 |
| Jazz Pharmaceuticals Inc. | 1 | $125 |
| Merck | 1 | $124 |
| Pfizer | 1 | $122 |
| Sanofi | 1 | $120 |
| EUSA Pharma (US) LLC | 1 | $117 |
| Agios Pharmaceuticals, Inc. | 1 | $107 |
| AbbVie | 2 | $101 |
| Galvanize Therapeutics, Inc | 1 | $96 |
| E.r. Squibb & Sons, L.L.C. | 2 | $58 |
| Lupin Inc. | 1 | $28 |
| AstraZeneca | 1 | $19 |
| Amgen | 1 | $13 |
| Seagen Inc. | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology-oncology providers in Virginiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 51 | $628,093 |
| PomalystPomalidomide | 22 | $504,204 |
| QinlockRipretinib | 11 | $457,839 |
| TagrissoOsimertinib Mesylate | 23 | $391,407 |
| LenvimaLenvatinib Mesylate | 14 | $384,735 |
| ScemblixAsciminib Hydrochloride | 17 | $362,449 |
| RevlimidLenalidomide | 22 | $359,844 |
| JakafiRuxolitinib Phosphate | 14 | $271,697 |
| BrukinsaZanubrutinib | 16 | $208,328 |
| ImbruvicaIbrutinib | 14 | $205,149 |
| XareltoRivaroxaban | 25 | $31,325 |
| EliquisApixaban | 37 | $24,762 |
| Everolimus | 17 | $10,490 |
| Sucralfate | 12 | $4,521 |
| Fentanyl | 20 | $2,571 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $58 | $504,20422 claims |
| AstraZenecaTagrisso | $19 | $391,40723 claims |
| NovartisScemblix | $1,180 | $362,44917 claims |
| Incyte CorporationJakafi | $125 | $271,69714 claims |
| PfizerEliquis | $122 | $24,76237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology-oncology providers in Virginiaon file to place this against a meaningful peer group, so we don't.
Other hematology-oncology in Chesapeake
- Edward GeorgeNorfolk$323K
- Ravneet GrewalLansdowne$10K
- John PascholdWilliamsburg$6K
- Paul ConklingNorfolk$4K
- Burton AlexanderNorfolk$612
- David PowellHampton$610
- Michael LeeNorfolk$501
- Scott CrossNorfolk$388
- John KesslerNewport News$194
- Kathryn CappellFairfax$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.